DefinitionThis section has been translated automatically.
Pharmacodynamics (Effect)This section has been translated automatically.
Inhibitor of the HIV-associated protease.
You might also be interested in
IndicationThis section has been translated automatically.
Combination therapy of HIV infection.
Limited indicationThis section has been translated automatically.
Nephrolithiasis and hyperuricemia in medical history, pregnancy, children.
Dosage and method of useThis section has been translated automatically.
- 3 times/day 800 mg p.o. as mono-protease inhibitor.
- Combination therapy with ritonavir: 2 times/day 400 mg indinavir + 2 times/day 100 mg ritonavir p.o.
Undesirable effectsThis section has been translated automatically.
Kidney pain and stones, hyperbilirubinemia > 2.5 mg/l, insomnia, pharyngitis, dry skin, altered taste perception.
Notice! Stop therapy if hyperbilirubinemia > 5 mg/l.
InteractionsThis section has been translated automatically.
When taking ketoconazole, reduce the dose of indinavir to 3 times/day 600 mg p.o.; when taking rifabutin in parallel, reduce rifabutin by half.
PreparationsThis section has been translated automatically.
Crixivan
PatientinformationThis section has been translated automatically.
Remember! High liquid intake (min. 3 litres/day). Take 1 hour before or 2 hours after meals. Exception: light breakfast with cornflakes, milk, sugar, coffee!
LiteratureThis section has been translated automatically.
- Eron JJ JR. (2002) HIV-1 protease inhibitors. Clin Infect Dis 30: 160-170
Prof. Dr. med. Peter Altmeyer